Evolving pharmaceutical therapies for confronting COVID-19: An overview

• Main Authors: Ghai, Roma, Nagarajan, Kandasamy, Mishra, Tejesvi, Vats, Srishti, Kaushik, Abhimanyu
• Format: Conference Proceeding
• Language: English
• Subjects: Coronaviruses; COVID-19; Disease transmission; Emergency medical services; Health services; Kinases; Medical research; Monoclonal antibodies; Mutation; Severe acute respiratory syndrome coronavirus 2; Viral diseases; Viral infections; Viruses
• ISSN: 0094-243X; 1551-7616
• DOI: 10.1063/5.0117619

December 2019 was marked by the arrival of the novel coronavirus, which has now reportedly resulted in 4,200,412 deaths (as ofJuly 30, 2021) world-wide. Although the casualty rate of SARS-CoV-2 is lower than other viral infections, yet its uncertainty poses a global threat. The virus that causes Covid-19 diseases is spreading among people, and more people are becoming infected. According to clinical studies, SARS-CoV-2 develops and migrates through the respiratory tract along the conducting airways, eliciting a robust innate immune response that leads to severe clinical manifestations such as cytokine storms, the release of chemical mediators including IL-2 and IL-6 at vital organs, and worsens in patients with co-morbidities. The treatment is largely focused on the assessment of patients since the studies are evaluating a wide array of medications for possible outcomes during this emergency period of the Covid 19 epidemic. On the contrary, few conventional drugs have been disapproved, such as hydroxychloroquine while others like ribavirin and lopinavir, are effective in combination therapies as per the studies. Monoclonal antibodies, kinase inhibitors, and basic febrifuges, along with anti-tussive syrups, have become a growing therapy for coronavirus patients. Although this virus seems to have a specific treatment due to the effects of viral variation and mutation, it's causing a leading global challenge for researchers. This article aggregates the conventional and new breakthrough therapeutics for tackling Covid 19 and its emerging therapeutic rationale reviewed by WHO, ICMR, FDA, PubMed, Google scholar, and the Covid update newsletter.